Remission Through Early Monitored Insulin Therapy - Duration Month
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REMIT-DM
- 13 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Sep 2019.
- 13 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2019 Planned End Date changed from 1 Apr 2019 to 1 Jun 2020.